Control of cancers by combining antiangiogenesis and cancer immunotherapy

Michelle Moniz, Jessica Yeatermeyer, T. C. Wu

Research output: Contribution to journalReview articlepeer-review


Ideally, cancer therapy would eliminate tumor growth at multiple sites in the body without damaging normal cells. In this regard, antiangiogenesis and immunotherapy may represent two potential approaches for control of cancers. Inhibition of tumor-specific angiogenesis restrains neoplastic growth by sequestering cancerous cells from an adequate blood supply, while activation of cancer-specific T cell-mediated immune responses can initiate attacks on tumors associated with a specific antigen. A novel approach that combines both strategies may potentially generate a better antitumor effect. In this review, we will outline the fields of cancer antiangiogenesis and cancer immunotherapy, including their advantages and limitations. In addition, we will discuss the feasibility of combining both mechanisms to generate a more powerful strategy for cancer therapy.

Original languageEnglish (US)
Pages (from-to)471-494
Number of pages24
JournalDrugs of Today
Issue number7
StatePublished - Jul 1 2005

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Control of cancers by combining antiangiogenesis and cancer immunotherapy'. Together they form a unique fingerprint.

Cite this